Opyl introduces Opin clinical trial match making service

Opyl has unveiled Opin: a patient-led platform giving people the ability to self-select an interest in any clinical trial or research study anywhere in the world.

“Opin is a great example of how AI and access to data can be applied sensitively to generate exponential and shared value from discovery and development of new medicines through to helping an individual patient better manage their healthcare and feel more in control.” – CEO Michelle Gallaher.

This is only an excerpt. The original article is written by TechInvest and can be found here.